合盛硅業(603260.SH):子公司擬斥175億元投建硅基新材料產業一體化項目
格隆匯2月14日丨合盛硅業(603260.SH)公佈,基於行業發展現狀及未來市場需求不斷增長的情況,結合公司發展戰略規劃,為進一步拓展公司全產業鏈佈局,提升公司競爭優勢,公司擬通過全資子公司新疆中部合盛硅業有限公司在新疆烏魯木齊市甘泉堡經濟技術開發區(工業區)內進行“新疆中部合盛硅業有限公司硅基新材料產業一體化項目(年產20萬噸高純多晶硅項目)”投資建設,項目預估總投資175億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.